Eric Van Cutsem

Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor)

Sabine Tejpar, Frans van Roy, Benjamin A Alman, 1999, Oncogene.

Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic chemotherapy ± biologic: Findings from 9,092 pts in the ARCAD database.

Qian Shi, Daniel J. Sargent, Fang-Shu Ou, 2017 .

Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis.

Satoshi Morita, Yasuo Ohashi, Junichi Sakamoto, 2013, Journal of the National Cancer Institute.

Molecular and clinical determinants of survival following relapse after treatment of stage ii-iii colon cancer (cc). results of the translational study on the petacc 3-eortc 40993-sakk 60-00 trial

Sabine Tejpar, Dirk Klingbiel, M. Delorenzi, 2010 .

Dasatinib combined with gemcitabine (Gem) in patients (pts) with locally advanced pancreatic adenocarcinoma (PaCa): Design of CA180-375, a placebo-controlled, randomized, double-blind phase II trial

Alexander S. Rosemurgy, Peter J. O'Dwyer, Eric Van Cutsem, 2012 .

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC

Sabine Tejpar, N. Normanno, F. Ciardiello, 2009, Nature Reviews Clinical Oncology.

Fetal electrocardiogram measuring method and equipment (FEMME)

Joos Vandewalle, Willy Sansen, Dirk Callaerts, 1987 .

Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC)

Daniel J. Sargent, Olivier Bouché, Alberto Sobrero, 2012 .

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

Yoon-Koo Kang, Taroh Satoh, Lin Shen, 2010, The Lancet.